AKRO

Akero Therapeutics, Inc. (AKRO) | Rumor.io

Akero Therapeutics

AKRO

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)96%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about AKRO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Feb 14

$AKRO is mentioned as a potential trading opportunity with analyst target prices being discussed.
Analysts are setting target prices for $AKRO on various days, including today and Monday.
$AKRO is being compared to other stocks, including $USTC and $TAI, with target prices being discussed.

Generated by AI

Sentiment

Of the messages about AKRO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	100%	77.08% -1.37
Bearish	0%	0% 0	0%	22.92% +1.37

Bullish· Oct 9

The acquisition of Akero Therapeutics by Novo Nordisk for up to $5.2B in cash is a significant bullish signal for the company.
Akero Therapeutics' stock price has surged 16-18% following the acquisition announcement, indicating informed call buying and a strong response from the market.
The company's 61% (10th %ile) SVI level suggests that options traders view the company's volatility as relatively cheap, providing a potential opportunity for traders.

Bearish· Jan 31

$AKRO's price may be artificially propped up, and when the rug gets pulled, JPM and pals will cover at prices well below $48.
The stock has doubled without a correction, suggesting it's being propped up, and this won't last.
Low volume and insider selling are bearish signs, and the stock may continue to fall in the absence of new information.

Generated by AI

Topics

Of the messages about AKRO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	31.13%
Announcements	—	—	100%	37.85%
Controversies	—	—	0%	0.39%
Earnings	—	—	0%	0.16%
Macro	—	—	0%	29.94%
Technical Analysis	—	—	0%	0.53%

Analysts· Sep 14

Evercore ISI Group analyst Liisa Bayko upgraded Akero Therapeutics to Outperform and raised the price target from $10 to $50.
Morgan Stanley analyst Matthew Harrison maintained Akero Therapeutics with an Equal-Weight rating and raised the price target from $26 to $30.
Raymond James lifted its price target on Akero Therapeutics from $14 to $25.

Announcements· Oct 10

Akero Therapeutics ($AKRO) has been acquired by Novo Nordisk for up to $5.2 billion, with $54 in cash per share and an additional $6 in CVR's.
The acquisition is seen as a strategic move to combine Akero's Efruxifermin with Novo Nordisk's Wegovy, potentially increasing the uptake of the latter by a significant portion of the population.
Law firms are investigating the fairness of the $54/share deal, with some questioning the terms despite the stock's 16.68% increase following the announcement.

Technical Analysis· Jan 27

$AKRO has been propped up and pinned around $50, with potential for a drop to $43 if support is breached.
Technical analysis suggests $AKRO is likely to tick down near the end of the day, potentially offering a shorting opportunity.
$AKRO is consolidating sideways above its volume-weighted average price (VWAP), with key support levels identified at $53.13.

Generated by AI

Community

Of the messages about AKRO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	87.5%	66.5%
Newcomers	100%	100%	12.5%	33.5%

Regulars· Oct 9

Akero Therapeutics ($AKRO) is being acquired by Novo Nordisk ($NVO) for up to $5.2 billion, with a cash payment of $54 per share and a contingent value right (CVR) of $6 per share upon regulatory approval.
The acquisition is expected to close by year-end, and shareholders will receive a cash payment of $54 per share and a CVR of $6 per share, with regulatory approval required by June 30, 2031.
The deal is seen as a key validation of the compensated cirrhosis market, with the industry recognizing the potential for liver-targeted MASH drugs to achieve commercial success.

Newcomers· Oct 10

The acquisition of Akero Therapeutics by Novo Nordisk is expected to strengthen Novo Nordisk's pipeline in the treatment of MASH, a severe liver disease with no approved treatments.
The deal may ensure Wegovy uptake by a significant portion of the population through combination therapy with Efruxifermin, making it a strategic masterplan for Novo Nordisk.
The buyout offers $54 cash per share plus a CVR of $6 if EFX gets MASH approval by 2031, which could be a game-changer for liver disease treatment and drive a potential 18%+ rise in Akero Therapeutics' stock.

Generated by AI

News

NextCure Announces Transformative All-Stock Merger With Avere

Detailed price information for Nextcure Inc (NXTC-Q) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

Also Discussed

Investors talking about AKRO also mention

#	Name	Attention
1	ETNB - 89bio, Inc.	——
2	Equifax Inc.EFX	0.01%0
3	Madrigal Pharmaceuticals Inc.MDGL	0%-0.02
4	United Natural Foods Inc.UNFI	0%new
5	RAYE - Rayliant Quantamental Emerging Market Equity ETF	——
6	PNT - POINT Biopharma Global Inc.	——
7	yearn.financeYFI	0%0
8	TD SYNNEX CorporationSNX	0%0
9	Organon & Co.OGN	0%0
10	TERN - Terns Pharmaceuticals, Inc.	——